Member Info for The_Paladin

Today, I have the impression that holding for 2+ years has been a waste of time and money.

As an investor, I have been well and truly out played by a master manipulator. The stream of positive information over an extensive time period, in particular by IB, counts for nothing today.

I shall continue to hold, and to see what develops after today’s maelstrom? For sure, at least one covetous individual will benefit hugely from today’s RNS. GLALTIs.

Agreed. On balance, it remains as a Hold for me. I am still questioning why we are again down at the current share price from 5p at the turn of the year? Should it be the case of Mr. Brown squeezing out more profit from his position at the company and at the expense the share price, investors will no doubt question his integrity?

With the positive news available to potential investors in recent months, surely the share price shouldn’t have diminished by > 50% from the start of the year? GLALTIs.

I mentioned that informal conversation at the AGM a week or so ago. I believe that it was Simon Shaw who stated that further trials were necessary to provide additional data to satisfy potentially interested BP partners? Attendees at the AGM will no doubt correct me if I am wrong.

Tomorrow would be an excellent date for a positive RNS concerning the forthcoming trials should the company be in a position to issue one? It will be exactly two years since the Sprinter top line data announcement that scuppered my Synairgen investment, together with those of fellow LTIs.

I am not concerned too much about the company’s financial situation at present, other than the issues that I have already written about. I continue to question the company’s current MCap. It is based solely on the cash balance, and there is no value attached to the company’s patents, and the existing data from previous trials? Does the company attribute any value to these assets? Have they been approached by a BP suitor, and rejected an offer that was deemed insufficient in relation to their own valuation?

Without doubt, we are in a tight situation. However, should the trial launch go ahead during H1, as scheduled, we should have a decent chance of recovery. Onwards and upwards.

GLALTIs

Agreed Gunto, but most investors’ prior expectations, including yours, have slipped into Q2, 2024. That is fine by me, as long as there is a successful resolution to the current P2 trial strategy.

At present, any discussion relating to Synairgen’s P2 trials or the company’s financial position are pointless. We simply do not have sufficient information to comment meaningfully about future trials, how they will be financed, or their time frames?

As we are highly unlikely to receive an interim update as to how the company is currently faring, there is nothing else to do but to regularly check for an RNS. At first I was optimistic of the trials starting this Winter, but we now appear to be missing yet another boat. GLALTIs.

ValiRx updated investors by RNS earlier today.

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that, further to the announcement of 9 February 2024, the Company has now received legal advice regarding the validity of the requisition notice it received, which notice has been CONFIRMED AS INVALID. The requisitioning shareholders have been informed and shareholders are advised to take no action at this time.

Manifesto.

Your calculation is based on Synairgen funding the P2 trials themselves - from their last statement to investors. The trials’ cost, and associated company running costs would have been thoroughly scrutinised and approved prior to that statement. There is nothing about Synairgen’s previous trials to suggest that they would be anything other than rigorous about their funding.

The recent addition of a new CFO and CMO to the BOD could well bring about changes to the funding structure? Everybody’s opinions on this forum are mere guesswork until we have a definitive update from the company,

Unfortunately, I do not perceive any incoming bids, based on what Simon Shaw informally told investors at the last AGM.

The 18 month initiative in which all company data was extracted from previous trials, presented in journals, and discussed with potential partners at relevant conferences wasn’t enough for a sought after BP partner to commit.

The P2 trial data is essential to provide additional reassurance to BP to enter a JV agreement IMHO.

The long wait continues to frustrate all LTIs, but it is as it is. One day, now probably during late Q2 , 2024 IMHO, the company will launch the P2s. Should they fail to do so, Mr. Marsden and the BOD are likely to lose all the remaining credibility, and good will, that they retain with most retail investors like myself.

GLALTIs.

Jint.

Thank you for your comments yesterday evening. I have been mulling over our (ie Synairgen LTIs’) situation since the start of the year, and have concluded that the scenario that you presented is the best way to proceed until the next AGM.

Every Synairgen investor wants an update at this point in time. Looking at the low level of communication over the last two years, we are unlikely to receive any news until the trials are ready to launch. Additionally, I don’t see that removing the CEO, the Board, or any of the senior execs would change anything. We are now two years down the road from a major P3 trial failure, and a credible way forward has been presented to investors. Some scientifically interested contributors on this forum are reasonably optimistic about its viability. We will soon know whether the company has the wherewithal to carry their plans forward.

GLALTIs.

It is unfortunate that this process is still ongoing. If, as some suspect, Mr Brown and his family are behind it, they are acting in their own interest and are not currently working towardsgrowing this investment.

I am firmly with Trek’s views as to the future viability of this investment. When the seller stops playing their self-serving games, and further information on the progress of trials, and IB technology emerge, we may well see a substantial re-rate in the share price? Hopefully, sometime during 2024? GLALTIs.

Agreed Luckybob23.

The traders have been in control for far too long, and it is not surprising that Mr. Zamboni’s integrity is regularly being questioned in relation to the latter.

This has been a long hold, and investors, who adopted a swing trading approach will have benefited.

A resolution still seems a long way off, and we need positive feedback on sustainable developments to remove SYME from the unrelenting grip of the traders.

GLALTIs.

Very interesting Brand and Tommy and a possible future development.

Currently, all LTIs are more interested in the progress of the current strategy. Notification of the commencement of the P2 trials will relaunch the company. There have been nearly two years of various approaches to get the company back on track. Unfortunately, with little success to date. However, the collation of previous data will have resulted in a valuable asset should the P2s be successful. The detailed mixed-media information generated is still up to date, and will serve to inform future investors.

I am inclined towards an H1 trial launch despite some doubts being expressed yesterday. Doc.Daneeka’s information on what needs to be undertaken beforehand is unequivocal, and his prediction (half way through Q2) seems reasonable, based on the company’s information from late September.

There may yet be a slip twixt cup and lip, but for the time being these are reasonable assumptions to carry us forward.

GLALTIs

“12month and 6month charts reflect an outcome that was clearly obvious 12 months and 6months ago.”

I would add that it is easy to be wise in hindsight, especially when you made the right call. Investors who sold their shares a year ago and bought back recently will obviously have reaped a huge benefit in terms of their Synairgen shareholdings.

I am no expert but assume that these predictions are based on the fact that the company currently has no earnings; additionally on projections of net capital expenditure over the two time periods?

The projections do not take into account that there may have been a positive development for the company during the 12 month period, which could have changed the market perception? This is why I remained invested; presumably other investors, including TFG Holdings, adopted a similar approach? Whether we will be ultimately benefit from our investment decisions remains to be seen?

“TP have you ever seen Groundhog Day with Bill Murray?”

Yes Gunto I have. I am reminded of that film by the fact that one year ago I was waiting for news about a Synairgen trial, which I was expecting to happen during Winter 2022-2023. That trial did not materialise. We were never informed about what became of it?

Exactly one year later, I am waiting for news about another Synairgen trial, albeit scheduled for H1 2024 this time. I am hoping that this here won’t be a repeat performance of a year ago.

Seriously though Gunto, we are all on the same side on this forum. Why some contributors choose to defend the indefensible is beyond my comprehension but I do not challenge their right to do so.

Should my Synairgen investment eventually come good, I shall express a little contrition for my remarks concerning my continued disappointment with the company’s leadership team. Until then, I shall treat this forum as a discussion board. We are all free to express our opinions here. There is also the means for anyone to filter a contributor’s view that doesn’t concur with their own. GLALTIs.

We can try and rationalise the situation in terms of low trading volumes. However 14.85% down on the day from a year-low position just adds insult to injury.

It is difficult to justify the CEO and Board’s actions over the last two years. Surely, a better strategy was possible? There is no point in anyone responding by asking me or any other investor what we would have done in their place? They were in the driving seat. They have created a behometh of a senior leadership group without justification to investors. There has been no communication or reassurance for nearly five months. Is there any wonder that investors are now fearing that the remainder of their investment is being decimated by the market because of the total inaction of an underwhelming CEO, his BOD , and his team of highly rewarded executives?

I am open to all hypotheses as to what might be going on behind the scenes, as we wait for a company update.

It seems highly unlikely that there will be any incoming offer at this stage in the process. IMHO, that would have been more likely in 2022-2023 at the time of the trial data analysis announcements coupled with all the publicity the company arranged via different media outlets.

The scenario outlined by Synairgen last September is the most likely way forward. The company needs successful P2 trial data to generate a JV or T/O offer from a BP company IMHO.

I would be happy to be proven wrong provided any incoming offer restored my investment capital. As stated, I can’t see that happening at this stage of a long process. GLALTIs.

“It would be nice but I don't see the value in vague updates, particularly with the SP so open to abusive manoeuvres.”

A very fair comment. This has happened with two other companies in which I was invested. Good news emerged in each case, but the result was a sharp mid-term decrease in the share price, presumably due to market manipulation? I hadn’t associated this type of insidious manoeuvring with Synairgen, but confirm that it could well happen.

Once again, you have demonstrated a very optimistic outlook Fruitsnveg. It is difficult for me to share your optimism at present, despite being heavily invested.

Nothing would please me more than the emergence of some positive news from the company, and with it a sharp turnaround of Synairgen’s current all time low market valuation. It may yet prove to be an excellent time to buy stock as some here predict? However, realistically we need an update from the company - sooner rather than later. They can’t give us market sensitive information, but a it is not unreasonable for a company to offer investors a progress report.

CFO, SVP Finance, Financial controller, plus two chartered accountants on the BOD? What on Earth for? Curiouser and curiouser?

Much of the prolific selling observed since the last share price high point has no logic attached to it. From an investor’s point of view that is.

We have received so many positive indications, all of which suggest a share price increase. Yet someone (Mr. Brown, our CEO, is everyone’s best guess) continues to sell in sufficient quantity to seriously depress the share price. Presumably, the seller is benefiting from the process, despite the fact that the selling is counter intuitive to our available information as investors, that is? I fully understood the rationale regarding the selling associated with the CLN clearance but what is going on here? A swing trading ploy is my best guess, but I really don’t have much of a clue? GLALTIs.